Compugen Ltd. (CGEN) Stock Price & Analysis
Compugen Ltd. (CGEN) closed at USD 1.96 on Thursday, October 22, 2026, down 7.55% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 1.96; the Oct 22, 2026 session ranged USD 1.92–2.14 on volume of 285,492 shares. Market capitalization is —, with a 52-week range of USD 1.43–3.24 (NCM). Source: Nexqual, retrieved October 23, 2026 at 09:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CGEN.md
Key facts (CGEN)
- 1 of 80 tracked superinvestors hold CGEN (13F, Q3 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $74K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 4.6 (range 4–6).
- Total return with dividends: 1Y +17.4% vs S&P 500 +14.9%; 5Y -68.1% vs S&P 500 +80.3%.
- Next earnings: 2026-11-09, EPS estimate USD -0.09, revenue estimate $975K.
Superinvestors (SEC 13F-HR, Q3 2026) (CGEN)
1 of 80 tracked investors hold CGEN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| David Katz | Matrix Asset Advisors | 0.02% | $223K | Unchanged |
Insider sales (SEC Form 4, open-market, last ~7 months) (CGEN)
7 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-09 | Levine Zurit | SVP, Business Development | 1,875 | $5K | 6% | Yes (adopted December 23, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-24 | Levine Zurit | SVP, Business Development | 2,000 | $6K | 6.4% | Yes (adopted December 23, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-24 | Ophir Eran | President and CEO | 5,000 | $16K | 30.5% | Yes (adopted December 26, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-14 | Ophir Eran | President and CEO | 5,000 | $15K | 30.5% | Yes (adopted December 26, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-14 | Levine Zurit | SVP, Business Development | 2,000 | $6K | 6.4% | Yes (adopted December 23, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-10 | Levine Zurit | SVP, Business Development | 3,125 | $8K | 9.6% | Yes (adopted December 23, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-07…2026-04-08 | Levine Zurit | SVP, Business Development | 7,875 | $19K | 21.1% | Yes (adopted December 23, 2025) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (CGEN)
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 4.6 (low 4, high 6).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | HC Wainwright & Co. | Reiterated | Buy | $4 |
Total return (dividends reinvested) (CGEN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +17.4% | -68.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +17.4% | -20.4% |
| Volatility (annualized) | 63.8% | 78.8% |
| Max drawdown | -36.8% (Apr 2026→Jun 2026) | -91.4% (Nov 2021→Oct 2022) |
CGEN suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | ASTRAZENECA PLC (AZN) | “We currently have two therapeutic program-based partnership agreements in effect, one with AstraZeneca plc, or AstraZeneca, and the second” |
| Partner | MedImmune | “with an amendment to our previously existing exclusive license agreement with MedImmune Limited, the global biologics research and development” |
| Partner | Pfizer (PFE) | “Notably, recent years saw multiple high-profile alliances, for instance, Pfizer's $1.25 billion licensing of a cancer antibody” |
| Partner | Leerink Partners | “finance our needs through the issuance of equity securities, including through our Sales Agreement with Leerink, debt securities or other” |
| Partner | Johnson & Johnson (JNJ) | “Ltd., an Israeli biotechnology accelerator established by OrbiMed Israel Partners, Johnson & Johnson Innovation, Takeda Ventures Inc.,” |
Quoted from the company's 20-F filed Mar 2, 2026.
CGEN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.09 | $-0.09 | +2.0% | $975,000 | 3 |
| Next quarter (ends Dec 2026) | $-0.09 | $-0.09 | +2.0% | $3.5M | 3 |
| Current fiscal year (ends Dec 2026) | $-0.33 | $-0.34 | -2.9% | $9.2M | 3 |
| Next fiscal year (ends Dec 2027) | $-0.37 | $-0.36 | +0.5% | $7.8M | 3 |
CGEN options: expected move
Options price a move of about ±27.6% (±$0.55) by Dec 18, 2026, which includes earnings on Nov 9, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Dec 18, 2026 | 56 | 71.7% | ±27.6% |
| Mar 19, 2027 | 147 | 86.8% | ±52.8% |
30-day implied volatility 64.2% vs 50.7% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:48 UTC)
| Price | USD 1.96 |
|---|---|
| Change | ▼ 7.55% (down) |
| Previous Close | USD 1.96 |
| Open | USD 1.96 |
| Day Range | USD 1.92 – 2.14 |
| 52-Week Range | USD 1.43 – 3.24 |
| Volume | 285,492 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (CGEN)
Nexqual's technical model rates CGEN "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.59 (neutral) |
| vs SMA50 | Below (USD 2.38) |
| MACD | -0.11 (negative) |
Analyst Ratings (CGEN)
Wall Street analysts rate CGEN "Buy" based on 5 analysts, with a mean price target of USD 4.6 (range USD 4–6), per Nexqual as of October 23, 2026 at 09:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 4.6 |
| High Target | USD 6 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (CGEN)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -0.09 |
| Revenue Estimate | $975,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.07 vs est -0.09 ▲ beat |
| 2026-03-31 | USD -0.08 vs est -0.08 ▲ beat |
| 2025-12-31 | USD 0.6 vs est 0.14 ▲ beat |
| 2025-09-30 | USD -0.07 vs est -0.09 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financials & Fundamentals (CGEN)
| Total Revenue | $74.00M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +107.00% |
| Gross Margin | +86.89% |
| Operating Margin | -339.62% |
| Profit Margin | +47.55% |
| ROE | +50.64% |
| Debt / Equity | 0.03 |
| Current Ratio | 5.72 |
| Total Cash | $125.30M |
| Total Debt | $3.02M |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Ownership (CGEN)
| Insider Ownership | +0.39% |
|---|---|
| Institutional Ownership | +15.17% |
| Shares Outstanding | 94.72M |
| Float | 94.51M |
| Short % of Float | +2.49% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Leadership (CGEN)
Compugen Ltd. is led by Eran Ophir, CEO, President & Director, per Nexqual as of October 23, 2026 at 09:48 UTC.
| CEO, President & Director | Eran Ophir |
|---|---|
| Chief Operating Officer | Pierre Ferre |
| Senior Vice President of Business Development | Zurit Levine |
| Chief Financial Officer | David Silberman |
| Vice President of Human Resources | Dorit Amitay |
Major Backers & Investors (CGEN)
Notable institutional backers of Compugen Ltd. include SilverArc Capital Management, LLC, Renaissance Technologies, Morgan Stanley, according to Nexqual as of October 23, 2026 at 09:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SilverArc Capital Management, LLC | 3.4% |
| Renaissance Technologies | 2.01% |
| Morgan Stanley | 1.12% |
| Nomura Asset Management International Inc | 1.09% |
| Delaware Group Equity Funds IV-Nomura Healthcare Fund | 1.09% |
| Taylor Frigon Capital Management LLC | 0.9% |
| ARK Invest | 0.84% |
| Altshuler Shaham Ltd | 0.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| State Street | 0.44% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CERS | Cerus Corporation | USD 2.31 | ▼ 3.35% |
| SYRS | Syros Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| VCYT | Veracyte, Inc. | USD 46.04 | ▼ 0.39% |
| MCRB | Seres Therapeutics, Inc. | USD 2.13 | ▼ 7.39% |
| EVGN | Evogene Ltd. | USD 0.38 | ▲ 1.59% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt